Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL-2: VRDN-003 in Chronic Thyroid Eye Disease
NCT06625398Phase 3Active, not recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of elegrobart in thyroid eye disease (TED) (3 arms), sponsored by Viridian Therapeutics. Primary endpoint: Proptosis Responder Rate in the most proptotic eye as measured by exophthalmometer at 24 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
elegrobart
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06625398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625398.